• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary pharmacology & therapeutics >Anti-immunoglobulin E therapy for asthma.
【24h】

Anti-immunoglobulin E therapy for asthma.

机译：抗免疫球蛋白E治疗哮喘。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The role of immunoglobulin E (IgE) in allergic asthmatic disease is well established. Allergen-specific IgE binds to its cognate receptors, thus triggering a series of cellular events. These events include presentation of antigen by dendritic cells and the degranulation of mast cells and basophils to release numerous factors that play an integral part in potentiating the disease symptoms. Studies in the mouse indicate that a reduction in IgE levels could lead to significant attenuation of the allergic inflammatory response associated with diseases such as asthma, making IgE a target for the development of new therapeutic agents. Omalizumab (Xolair, a recombinant humanized monoclonal anti-IgE antibody that blocks the interaction of IgE with its receptors, is the first anti-IgE agent to undergo clinical development. Several clinical studies have been performed in adults and children with moderate-to-severe allergic asthma to evaluate the efficacy and safety of this agent. Treatment with omalizumab was well tolerated and showed clinical benefit in terms of a reduction in the frequency and number of asthma exacerbation episodes and lower usage of corticosteroids and other medications to control disease, along with improved quality of life. Such findings indicate that omalizumab represents a promising new treatment option for allergic asthma.
机译：免疫球蛋白E（IgE）在过敏性哮喘疾病中的作用已得到公认。过敏原特异性IgE与其同源受体结合，从而引发一系列细胞事件。这些事件包括树突状细胞呈递抗原，肥大细胞和嗜碱性粒细胞脱粒，释放出许多因子，这些因子在增强疾病症状中起着不可或缺的作用。小鼠研究表明，IgE水平降低可能导致与哮喘等疾病相关的过敏性炎症反应显着减弱，从而使IgE成为开发新治疗剂的目标。 Omalizumab（Xolair，一种可阻断IgE及其受体相互作用的重组人源化单克隆抗IgE抗体，是首个进行临床开发的抗IgE药物。已在成人和中至重度儿童中进行了多项临床研究过敏性哮喘，以评估该药的疗效和安全性奥马珠单抗治疗耐受性良好，并且在减少哮喘急性发作的频率和次数，减少使用糖皮质激素和其他药物控制疾病等方面显示出临床益处这些发现表明，奥马珠单抗是过敏性哮喘的一种有希望的新治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号